Arrowhead's pivotal sHTG data and a priority review voucher set the stage for REDEMPLO's expansion
Positive SHASTA-3/4 results, doubled launch prescriptions, and a $215M PRV to accelerate plozasiran's sNDA.
ARWR · Earnings Call · 2026-08-04
The pivotal readout that changes the conversation
Two weeks before this call, Arrowhead reported top-line Phase III results from SHASTA-3 and SHASTA-4 in severe hypertriglyceridemia (sHTG). The data were decisive: both studies met their primary endpoint and every prespecified secondary endpoint, with median triglyceride reductions of 79% and 81% versus ~27% for placebo. “Both studies met their primary endpoint and every prespecified secondary endpoint, a clean sweep across 2 pivotal trials.” — Dr. Christopher Anzalone, President and CEO · 2026-08-04 The standout result was a 78% reduction in cumulative acute pancreatitis events across the broad sHTG population, and a 100% reduction in the highest-risk subgroup (triglycerides >880 mg/dL with a prior pancreatitis history).
We believe the SHASTA results materially derisk our most important near-term label expansion opportunity and further strengthen the foundation of our cardiometabolic franchise.
That derisking is now formalized: Arrowhead acquired a priority review voucher (PRV) for $215M, which can cut the FDA's review time for the planned sNDA from 10 to 6 months. CFO Dan Apel quantified the rationale: “According to our projections, should we gain approval in sHTG, the increase in present value of REDEMPLO simply as a result of shifting our launch aspirations and uptake curve forward by 4 months, provides a greater than 3x return on the PRV investment.” — Daniel Apel, Chief Financial Officer · 2026-08-04 The company expects to file the sNDA before end of 2026, with potential launch as early as Q2 2027.
From ultra-rare to a broader cardiometabolic franchise
The FCS launch itself is compounding. On the call, Andy Davis noted that “REDEMPLO prescription volume has more than doubled over the course of the fiscal third quarter, and that momentum has continued into the current quarter.” — Andy Davis, Senior Vice President and Head of Commercial · 2026-08-04 The 8.5-month-old launch now counts over 400 unique prescribers, and commercial revenue (derived from disclosures) roughly doubled sequentially to ~$2.4M. The company is deliberately scaling its field force ahead of potential sHTG approval, moving from ~5,000 HCP targets to over 20,000.
This matches the durable switch dynamics we've seen from the start: “We've seen really diversity of reasons for switch that include efficacy, safety and tolerability” — Andy Davis, Senior Vice President and Head of the Global Commercial Organization · 2026-05-07, and patient origination remains predominantly “from APOC3-naive segment” — Andy Davis, Senior Vice President · 2026-02-05.
Beyond plozasiran, the pipeline is broadening: ARO-DIMER-PA (silencing both APOC3 and PCSK9) readout in September, ARO-MAPT (the first subcutaneously administered CNS conjugate) also in September, and ARO-INHBE/ALK7 data later this year. The company now expects 23 drug candidates in clinical trials by year-end. liver fat reductions from ARO-INHBE were highlighted as a key early signal.
Financial firepower and execution risk
Arrowhead ended the quarter with ~$1.6B in cash and investments, and the balance sheet was further bolstered by the $215M PRV commitment (paid at closing) and the recent Madrigal licensing deal for ARO-PNPLA3 ($25M upfront, up to $975M in milestones). R&D expense remains heavy at $198M for the quarter, and net loss widened to $194M. But the company's inflection point is now commercial rather than clinical.
Effective net cash reached $3.2B, reflecting the Sarepta milestone and other partnership inflows.
That financial flexibility is essential because the sHTG market is a brand-new to build. As Chris Anzalone put it: “This is going to be a relatively slow ramp because this is a brand-new market. We are in the education business.” — Dr. Christopher Anzalone, President and CEO · 2026-08-04 The competitive landscape also intensifies: Ionis's Tryngolza (olezarsen) is already in the market, and pricing pressure will be watched. Arrowhead retains a premium price ($45K WAC) on the strength of its efficacy and safety profile.
Execution now hinges on translating the SHASTA data into a label and onto the market faster than the competition. The PRV is a clear signal that management intends to do exactly that.